<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00877747</url>
  </required_header>
  <id_info>
    <org_study_id>HD-PET-intens-retr</org_study_id>
    <nct_id>NCT00877747</nct_id>
  </id_info>
  <brief_title>Early Chemotherapy Intensification in Interim-Positron Emission Tomography (PET) Positive Hodgkin Lymphoma</brief_title>
  <official_title>Early Chemotherapy Intensification With BEACOPP in High-risk, Interim-PET Positive Advanced-stage Hodgkin Lymphoma:a GITIL Retrospective Multicenter Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale Santa Croce-Carle Cuneo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale Santa Croce-Carle Cuneo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early interim-PET after two courses of chemotherapy is a powerful outcome predictor in
      advanced-stage Hodgkin Lymphoma (HL) patients treated with adriamycin (doxorubicin),
      bleomycin, vinblastine and dacarbazine (ABVD). Two-year Progression Free Survival of PET-2
      positive patients is only 12%, but the optimal treatment for this patient subset is still
      unknown.

      From January 2006 GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) suggested an early
      intensification of chemotherapy with BEACOPP [Bleomycin, Etoposide, Adriamycin (doxorubicin),
      Cyclophosphamide, Oncovin (vincristine), Procarbazine, and Prednisone](4 escalated + 4
      baseline cycles) for all the HL patients with a positive PET-2 after 2 ABVD courses. The
      investigators retrospectively recorded and analyzed these data in order to evaluate if this
      strategy could be of benefit for this subset of patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of progression/relapse</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interim PET positive and negative predictive value</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">160</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>PET2 negative</arm_group_label>
    <description>Patients with negative early interim PET after 2 courses of ABVD who continued therapy with ABVD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PET2 positive</arm_group_label>
    <description>Patients with positive early interim PET after 2 courses of ABVD who changed their therapy to BEACOPP</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced stage Hodgkin's lymphoma (IIB to IVB) or in stage IIA with adverse
        prognostic factors (more than 3 nodal sites, ESR &gt; 50 mm, bulky lesion)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with advanced Hodgkin's lymphoma according to the World Health Organization
             classification

          -  Age 16-80

          -  Not previously treated

          -  Stage IIB to IVB or stage IIA with adverse prognostic factors (more than 3 nodal
             sites, ESR &gt; 50 mm, bulky lesion)

          -  Written informed consent

        Exclusion Criteria:

          -  Patients aged more than 80

          -  Concomitant or previously treated neoplastic disorder less than 5 years before the
             diagnosis of Hodgkin's lymphoma

          -  Psychiatric disorders

          -  Uncontrolled infectious disease

          -  Impaired cardiac (EF &lt; 50%) or renal (creatinine clearance &lt; 60 ml/m)function

          -  Pregnancy and lactation

          -  Uncompensated diabetes mellitus and fasting glucose levels over 200 mg/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Gallamini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Santa Croce e Carle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007 Aug 20;25(24):3746-52. Epub 2007 Jul 23.</citation>
    <PMID>17646666</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2009</study_first_submitted>
  <study_first_submitted_qc>April 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2009</study_first_posted>
  <last_update_submitted>October 16, 2015</last_update_submitted>
  <last_update_submitted_qc>October 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale Santa Croce-Carle Cuneo</investigator_affiliation>
    <investigator_full_name>DR. ANDREA GALLAMINI</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

